Pharmaceutical composition containing mesenchymal stem cells as an effective ingredient for preventing or treating inflammatory diseases
By using mesenchymal stem cells expressing HLA-A2 to inhibit TNF-α secretion and promote CD163 and Arg-1 expression, the high adverse reactions and symptom recurrence of existing anti-inflammatory drugs were solved, and effective inflammation inhibition and treatment effects were achieved. .
Patent Information
- Application Number
- CN201980038809.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-06-05
- Filing Date
- 2019-06-05
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2039-06-05
AI Technical Summary
Existing anti-inflammatory drugs such as immunosuppressants and steroids have high adverse reaction rates and recurrence of disease symptoms after long-term use, and lack of effective inflammatory inhibitors.
Mesenchymal stem cells expressing HLA-A2 are used as active ingredient in the pharmaceutical composition to effectively inhibit inflammation by inhibiting the secretion of the inflammatory cytokine TNF-α and promoting the expression of anti-inflammatory markers CD163 and Arg-1.
HLA-A2-expressing mesenchymal stem cells significantly reduce TNF-α secretion, promote the expression of CD163 and Arg-1, provide effective inflammatory inhibition effects, and demonstrate excellent anti-inflammatory effects in mouse models, especially Treatment effects in bronchial lung dysplasia and Alzheimer's disease models.
Smart Images

Figure CN112261943B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases, comprising mesenchymal stem cells expressing HLA-A2 as an active ingredient. Background Art
[0002] Inflammation is usually a local protective response caused by foreign bodies or harmful stimuli. Direct causes of inflammation include infectious agents (such as bacteria, viruses and parasites); physical factors (such as burns or radiation); chemical substances (such as toxins and drugs); immunological reactions (such as allergies and autoimmune reactions), etc.
[0003] Generally, antibiotics are used for inflammation caused by bacterial infection, while anti-inflammatory enzymes are used for painless inflammation caused by pus, etc. In addition, non-steroidal anti-inflammatory drugs are used for inflammation with severe pain, and immunosuppressants or steroids are used for inflammation caused by abnormal immune system. However, immunosuppressants and steroids are problematic. Because immunosuppressants directly involve the immune system, they have a high incidence of adverse reactions; steroids also show adverse effects in the case of long-term use, and discontinuation of their use can lead to the recurrence of disease symptoms.
[0004] Recently, in order to overcome these adverse effects, treatment using stem cells has become a focus of attention in the biopharmaceutical market. Among stem cells, mesenchymal stem cells (MSCs) can differentiate into several cell lineages, such as adipocytes, osteocytes, and chondrocytes. In addition, mesenchymal stem cells have the advantage of being able to be isolated from many tissues, including, in addition to bone marrow, dense bone, peripheral blood, adipose tissue, umbilical cord blood, and amniotic membrane. Summary of the invention
[0005] Technical issues
[0006] The present inventors have found that mesenchymal stem cells expressing HLA-A2 exhibit superior anti-inflammatory effects in vitro than mesenchymal stem cells not expressing HLA-A2. In addition, the present inventors have also found that mesenchymal stem cells expressing HLA-A2 exhibit superior anti-inflammatory effects in a mouse model induced with bronchopulmonary dysplasia and a mouse model induced with Alzheimer's disease.
[0007] Solution
[0008] In one aspect of the present invention, it relates to a pharmaceutical composition for preventing or treating inflammatory diseases, comprising mesenchymal stem cells expressing HLA-A2 on the cell surface as an active ingredient.
[0009] In another aspect of the present invention, a method for preventing or treating an inflammatory disease is provided, comprising the step of administering the pharmaceutical composition to an individual.
[0010] In another aspect of the present invention, provided is the use of mesenchymal stem cells expressing HLA-A2 on the cell surface in preparing a medicament for preventing or treating inflammatory diseases.
[0011] In another aspect of the present invention, a method for screening mesenchymal stem cells having excellent inflammation suppression ability is provided, comprising the steps of: isolating mesenchymal stem cells expressing HLA-A2 on the cell surface.
[0012] Advantageous Effects of the Invention
[0013] The mesenchymal stem cells expressing HLA-A2 on the cell surface of the present invention inhibit the secretion of TNF-α, which is an inflammatory cytokine, and promote the expression of CD163 and Arg-1, which are anti-inflammatory markers. Therefore, the pharmaceutical composition containing the mesenchymal stem cells as an active ingredient can be effectively used to inhibit or treat inflammation.
[0014] BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 Shown are the results obtained by treating Raw264.7 cells that had been treated with LPS to induce an inflammatory response with mesenchymal stem cells expressing HLA-A2 (batches: G171, G28, and G257) or mesenchymal stem cells that do not express HLA-A2 (batches: G571, G43, and G240), wherein the amount of secreted mTNF-α was measured.
[0016] Figure 2 Shown are the results obtained by treating Raw264.7 cells that had been treated with LPS to induce an inflammatory response with mesenchymal stem cells expressing HLA-A2 (batches: G171, G28, and G257) or mesenchymal stem cells not expressing HLA-A2 (batches: G571, G43, and G240), wherein the reduction rate of mTNF-α secretion was calculated.
[0017] Figure 3 Shown are the results obtained by measuring the amount of mTNF-α secreted by Raw264.7 cells, in which an inflammatory response had been induced and co-cultured with mesenchymal stem cells expressing HLA-A2, which had been treated with control siRNA (HLA-A2(+)-MSC-siCON) or siRNA against HLA-A2 (HLA-A2(+)-MSC-siHLA-A2).
[0018] Figure 4Shown are the results obtained by calculating the reduction rate of mTNF-α secreted by Raw264.7 cells, in which an inflammatory response had been induced and co-cultured with HLA-A2-expressing mesenchymal stem cells treated with control siRNA (HLA-A2(+)-MSC-siCON) or siRNA against HLA-A2 (HLA-A2(+)-MSC-siHLA-A2).
[0019] Figure 5 Shown are the results obtained by analyzing the HLA-A2 expression pattern in mesenchymal stem cells at passage 2 (P2) and mesenchymal stem cells at passage 6 (P6).
[0020] Figure 6 The results of mouse lung tissue staining are shown. The results were obtained by administering PBS, mesenchymal stem cells expressing HLA-A2 (HLA-A2(+)-MSC), or mesenchymal stem cells treated with control siRNA (HLA-A2(+)-MSC-siCON) or siRNA targeting HLA-A2 (HLA-A2(+)-MSC-siHLA-A2) to a bronchopulmonary dysplasia mouse model, and then staining lung tissues harvested from the mice on day 14.
[0021] Figure 7 The results of measuring alveolar size in mouse lung tissue are shown. The alveolar size in mouse lung tissue was measured on day 14 after administering PBS, mesenchymal stem cells expressing HLA-A2 (HLA-A2(+)-MSC), or mesenchymal stem cells treated with control siRNA (HLA-A2(+)-MSC-siCON) or siRNA against HLA-A2 (HLA-A2(+)-MSC-siHLA-A2) to a bronchopulmonary dysplasia mouse model.
[0022] Figure 8 The results of measuring the levels of TNF-α and IFN-γ in the brain tissue of mice are shown. The results were obtained by administering physiological saline (control) and mesenchymal stem cells expressing HLA-A2 to an Alzheimer's disease mouse model, and administering the mesenchymal stem cells once (single) or repeatedly (repeatedly), and then identifying the expression levels of TNF-α and IFN-γ in the brain tissue collected from the mice at week 12.
[0023] Fig. 9The results of measuring the levels of TNF-α and IFN-γ in the brain tissue of mice are shown. The results were obtained by administering physiological saline (control) and mesenchymal stem cells expressing HLA-A2 to an Alzheimer's disease mouse model, and administering the mesenchymal stem cells once (single) or repeatedly (repeatedly), and then identifying the expression levels of TNF-α and IFN-γ in brain tissue collected from the mice at week 20.
[0024] Fig.10 The results of measuring CD163 and Arg-1 levels in brain tissue of mice are shown. The results were obtained by administering physiological saline (control) and mesenchymal stem cells expressing HLA-A2 to Alzheimer's disease mouse models, and administering the mesenchymal stem cells once (single) or repeatedly (repeatedly), and then identifying the expression levels of CD163 and Arg-1 in brain tissue collected from mice at week 12.
[0025] Fig.11 The results of measuring CD163 and Arg-1 levels in mouse brain tissues are shown. The results were obtained by administering physiological saline (control) and mesenchymal stem cells expressing HLA-A2 to an Alzheimer's disease mouse model, and administering the mesenchymal stem cells once (single) or repeatedly (repeatedly), and then identifying the expression levels of CD163 and Arg-1 in brain tissues collected from mice at week 20. DETAILED DESCRIPTION OF THE INVENTION
[0027] Hereinafter, the present invention will be described in detail.
[0028] In one aspect of the present invention, it relates to a composition for preventing or treating inflammatory diseases, comprising mesenchymal stem cells expressing human leukocyte antigen A2 (HLA-A2) on the cell surface as an active ingredient.
[0029] HLA-A2 is a human leukocyte antigen (HLA) serotype in the HLA-A serotype group, where HLA is a glycoprotein molecule encoded by the human major histocompatibility complex (MHC) gene complex. HLA-A is expressed on the surface of all nucleated cells and platelets, and plays a role in antigen recognition when cytotoxic T cells recognize and eliminate virus-infected cells or tumor cells. To date, there have been no reports on the inflammatory inhibitory effects of human mesenchymal stem cells expressing HLA-A2.
[0030] The present invention is based on the result that mesenchymal stem cells expressing HLA-A2 on the cell surface have excellent inflammation inhibition ability compared to mesenchymal stem cells that do not express HLA-A2. Specifically, in one embodiment of the present invention, the mesenchymal stem cells expressing HLA-A2 on the cell surface of the present invention are characterized in that the level of HLA-A2 expressed by these cells is increased by 70%, 75%, 80%, 85%, 90% or 95%, or more compared to mesenchymal stem cells that do not express HLA-A2.
[0031] In addition, the mesenchymal stem cells of the present invention may express on their surface any one selected from the following group: cluster of differentiation 73 (CD73), CD90, CD105, CD166, and combinations thereof; and may not express any one selected from the following group: CD14, CD34, CD45, human leukocyte antigen DR (HLA-DR), and combinations thereof.
[0032] Specifically, the mesenchymal stem cells of the present invention may express each of CD73, CD90, CD105 and CD166 at a level of 70% or more on their surface, and may express each of CD14, CD34, CD45 and HLA-DR at a level of 1% or less. More specifically, the mesenchymal stem cells of the present invention may express HLA-A2 at a level of 75% or more, may express each of CD73, CD90, CD105 and CD166 at a level of 70% or more, and may express each of CD14, CD34, CD45 and HLA-DR at a level of 1% or less on their surface.
[0033] CD73, also known as 5'-nucleotidase (5'-NT), is an enzyme encoded by the NT5E gene. The function of CD73 is to convert adenosine monophosphate (AMP) into adenosine.
[0034] CD90 is a cell surface protein composed of an N-glycosylated glycophosphatidylinositol (GPI) and a single V-type immunoglobulin domain.
[0035] CD105, also known as endoglin (ENG), is a type I membrane glycoprotein located on the cell surface and is part of the TGFβ receptor complex.
[0036] CD166 is a type I transmembrane glycoprotein located on the cell surface and is a member of the immunoglobulin superfamily of proteins. CD166 is encoded by the ALCAM gene.
[0037] CD14 is a pattern recognition receptor (PRR) and is a component of the innate immune system. To detect bacterial lipopolysaccharide (LPS), CD14 binds to LPS in the presence of lipopolysaccharide binding protein (LBP) together with co-receptors Toll-like receptor 4 (TLR4) and MD-2.
[0038] CD34 is a transmembrane phosphoglycoprotein encoded by the CD34 gene in humans.
[0039] CD45 is a protein tyrosine phosphatase (PTP) encoded by the PTPRC gene in humans.
[0040] HLA-DR is a cell surface receptor belonging to HLA class II, which is involved in autoimmunity, disease susceptibility, disease resistance, etc.
[0041] As the mesenchymal stem cells, mesenchymal stem cells of any origin may be used, but mesenchymal stem cells derived from umbilical cord blood are preferred.
[0042] In addition, the content of mesenchymal stem cells expressing HLA-A2 in the pharmaceutical composition can be 1.0×10 5 cells / ml to 1.0×10 8 cells / ml, and specifically can be 1.0×10 5 cells / ml to 1.0×10 8 cells / ml or 2.0×10 5 cells / ml to 5.0×10 7 Preferably, the content of mesenchymal stem cells expressing HLA-A2 in the pharmaceutical composition can be 5.0×10 6 cells / ml to 3×10 7 In one embodiment of the present invention, the content of 1×10 7 50 μl of a solution containing 10 cells / ml was administered to mice.
[0043] The pharmaceutical composition is a cell therapy agent and may further comprise a pharmaceutically acceptable carrier. The carrier is commonly used in the manufacture of drugs, and examples thereof include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, etc.
[0044] In addition, the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable additive selected from the group consisting of a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and a combination thereof.
[0045] Relative to the total weight of the pharmaceutical composition of the present invention, the content of the carrier can be about 1% to about 99.99% by weight, preferably about 90% to about 99.99% by weight, and the content of the pharmaceutically acceptable additive can be about 0.1% to about 20% by weight.
[0046] The pharmaceutical composition can be prepared into a unit dosage form by preparing it with a pharmaceutically acceptable carrier and excipient according to a conventional method, or the preparation can be placed in a multi-dose container. Here, the preparation can be in the form of a solution, suspension, syrup, or an emulsion in an oily or aqueous medium, or in the form of an extract, powder, granule or capsule; and can further contain a dispersant or a stabilizer.
[0047] Inflammatory diseases refer to diseases accompanied by inflammation. Inflammatory diseases may include, but are not limited to, rheumatoid arthritis, atopic diseases, asthma, allergic rhinitis, Alzheimer's disease, graft-versus-host disease (GVHD), diabetic nephropathy, Crohn's disease, inflammatory bowel disease, post-transplant rejection, bronchopulmonary dysplasia (BPD), or chronic obstructive pulmonary disease (COPD).
[0048] In another aspect of the present invention, a method for preventing or treating an inflammatory disease is provided, comprising the step of administering to an individual a pharmaceutical composition for treating an inflammatory disease, wherein the pharmaceutical composition comprises mesenchymal stem cells expressing HLA-A2 on the cell surface.
[0049] The mesenchymal stem cells expressing HLA-A2 are the same as those described in the above-mentioned pharmaceutical composition.
[0050] The individual may be a mammal, in particular a human. Regarding the route of administration and dosage of the pharmaceutical composition, the pharmaceutical composition may be administered to the subject in various methods and amounts according to the subject's condition and whether there are side effects; those skilled in the art may select the best administration method and dosage within an appropriate range. In addition, the pharmaceutical composition may be administered in combination with other drugs or physiologically active substances known to have a therapeutic effect on the inflammatory disease to be treated, or may be formulated with other drugs in the form of a combined preparation.
[0051] In case the pharmaceutical composition is administered parenterally, the pharmaceutical composition can be administered, for example, subcutaneously, ocularly, intraperitoneally, intramuscularly, orally, rectally, intraorbitally, intracerebrally, intracranially, intraspinally, intraventricularly, intrathecally, intranasally or intravenously.
[0052] Administration may be performed once or more, or 1 to 3 times, in particular 3 times. In the case of repeated administration, administration may be performed at intervals of 1 to 56 days, 7 to 49 days, 14 to 42 days, or 21 to 35 days. Preferably, administration may be performed at intervals of 28 days. In the case of high-dose administration, administration may be performed several times a day.
[0053] The dose of mesenchymal stem cells expressing HLA-A2 can be 1×10 6 cells / individual to 1×10 8 Specifically, the dose of mesenchymal stem cells expressing HLA-A2 can be 5×10 4 cells / kg to 1×10 7 cells / kg, 1×10 5 cells / kg to 7×10 6 cells / kg, or 2×10 5 cells / kg to 5×10 5 cells / kg.
[0054] In another aspect of the present invention, provided is the use of mesenchymal stem cells expressing HLA-A2 on the cell surface in preparing a medicament for preventing or treating inflammatory diseases.
[0055] In another aspect of the present invention, a method for screening mesenchymal stem cells having excellent inflammation suppression ability is provided, comprising the steps of: isolating mesenchymal stem cells expressing HLA-A2 on the cell surface.
[0056] Regarding the screening method, a method for isolating mesenchymal stem cells expressing HLA-A2 on the cell surface can be performed using, for example, flow cytometry.
[0057] In one embodiment of the present invention, mesenchymal stem cells are treated with anti-CD14 antibodies, anti-CD34 antibodies, anti-CD45 antibodies, anti-HLA-DR antibodies, anti-CD73 antibodies, anti-CD90 antibodies, anti-CD105 antibodies, anti-CD166 antibodies, and mouse anti-HLA-A2 antibodies to analyze their cell surface antigens. Then, only mesenchymal stem cells expressing HLA-A2, CD73, CD90, CD105, and CD166 are charged and passed through an electric field. In this way, mesenchymal stem cells expressing HLA-A2 on the cell surface are isolated.
[0058] Invention
[0059] Hereinafter, the present invention will be described in more detail by the following examples. However, the following examples are only for illustrative purposes, and the scope of the present invention is not limited thereto.
[0060] Example 1: Identification of HLA-A2 expression on the surface of mesenchymal stem cells derived from umbilical cord blood
[0061] For mesenchymal stem cells derived from umbilical cord blood, mesenchymal stem cells were first isolated from umbilical cord blood and then passaged 5 times. The passaged mesenchymal stem cells (generation 5) were cryopreserved in liquid nitrogen for use in batches. The cryopreserved mesenchymal stem cells were thawed in a constant temperature water bath at 37°C for about 3 minutes. Then, the mesenchymal stem cells were resuspended in α-MEM culture medium containing 10% (v / v) fetal bovine serum (FBS) and centrifuged at 1200rpm for 5 minutes. After centrifugation, the supernatant was removed and the remaining mesenchymal stem cells were resuspended in phosphate buffered saline (PBS).
[0062] Thereafter, in order to analyze the cell surface antigens of umbilical cord blood-derived mesenchymal stem cells, the cells were reacted with anti-CD14 antibody (BD Pharmaceuticals, Catalog No. #555397), anti-CD34 antibody (BD Pharmaceuticals, Catalog No. #555822), anti-CD45 antibody (BD Pharmaceuticals, Catalog No. #555482), anti-HLA-DR antibody (BD Pharmaceuticals, Catalog No. #555811), anti-CD73 antibody (BD Pharmaceuticals, Catalog No. #550257), anti-CD90 antibody (Invitrogen, Catalog No. #12-0909-42), anti-CD105 antibody (Invitrogen, Catalog No. #12-1057-42), anti-CD166 antibody (BD Pharmaceuticals, Catalog No. #555263), and mouse anti-HLA-A2 antibody (BD Pharmaceuticals, Catalog No. #558570) at 25°C in the dark for 15 minutes. After the reaction was completed, it was washed once with PBS and centrifuged at 1200 rpm for 5 minutes to separate only mesenchymal stem cells. Each test tube was treated with 200 μl of formaldehyde at a concentration of 1% to fix the cells. Here, cell surface antigens were analyzed using MACSQuantAnalyzer 10 flow cytometer (Miltenyi Biotechnology, Bergisch Gladbach, Germany) and MACSQuantify software. The analysis results are shown in Table 1 below.
[0063] [Table 1]
[0064]
[0065] As shown in Table 1, the level of HLA-A2 expression on the cell surface of the cord blood-derived mesenchymal stem cells in batches G171, G028, and G257 was identified to be 70% or more. On the other hand, the level of HLA-A2 expression on the cell surface of the cord blood-derived mesenchymal stem cells in batches G571, G043, and G240 was identified to be less than 1%. According to the above analysis, the difference between the mesenchymal stem cell population expressing HLA-A2 on the cell surface (HLA-A2 (+)) and the mesenchymal stem cell population not expressing HLA-A2 on the cell surface (HLA-A2 (-)) is obvious.
[0066] Example 2: Identification of the Inflammation-Suppressing Effect of Umbilical Cord Blood-Derived Mesenchymal Stem Cells Expressing HLA-A2 (I)
[0067] In order to compare the inflammation suppressive efficacy of mesenchymal stem cells depending on their HLA-A2 expression, the inflammation suppressive effect of the mesenchymal stem cells in each batch was examined.
[0068] Specifically, mouse-derived macrophage Raw 264.7 cells were treated with lipopolysaccharide (LPS), an inflammatory stimulant, to induce an inflammatory response. The mesenchymal stem cells in each batch that had been cryopreserved were thawed in a constant temperature water bath at 37°C for about 3 minutes. Then, the mesenchymal stem cells were resuspended in α-MEM medium containing 10% (v / v) fetal bovine serum (FBS) and centrifuged at 1200rpm for 5 minutes. After centrifugation, the supernatant was removed and the remaining mesenchymal stem cells were resuspended in RPMI medium.
[0069] Using RPMI medium containing 1 μg / ml LPS, 2×10 4 Raw264.7 cells were mixed with 2 × 10 of batches G171, G028, G257, G571, G043, or G240. 4 After 24 hours, the culture medium was collected and the amount of secreted mTNF-α was analyzed using a mouse TNF-α immunoassay kit (R&D Systems).
[0070] The results are as follows Figure 1 As shown, the amount of mTNF-α secreted in Raw264.7 cells co-incubated with mesenchymal stem cells from batches G171, G028 or G257 was further reduced compared with Raw264.7 cells co-incubated with mesenchymal stem cells from batches G571, G043 or G240.
[0071] In addition, based on the amount of secreted mTNF-α determined as above, the reduction rate was calculated. As a result, it was found that the group of mesenchymal stem cells expressing HLA-A2 on the cell surface (HLA-A2(+): G171, G028, G257) showed a reduction rate of mTNF-α secretion of about 35%, while the group of mesenchymal stem cells not expressing HLA-A2 on the cell surface (HLA-A2(-): G571, G043, G240) showed a reduction rate of mTNF-α secretion of 15% or less ( Figure 2 ).
[0072] Example 3: Identification of the Inflammation-Suppressing Effect of Umbilical Cord Blood-Derived Mesenchymal Stem Cells Expressing HLA-A2 on Their Cell Surfaces (II)
[0073] In order to identify whether inhibiting the expression of HLA-A2 in mesenchymal stem cells would inhibit the anti-inflammatory effect of mesenchymal stem cells, siRNA was used to inhibit the expression of HLA-A2 in mesenchymal stem cells to compare the inflammation inhibition effect.
[0074] Mouse-derived macrophages Raw 264.7 cells were treated with lipopolysaccharide (LPS), an inflammatory stimulant, to induce an inflammatory response. Then, mesenchymal stem cells expressing HLA-A2 (HLA-A2 (+) -MSC) were treated with control siRNA (SEQ ID NO: 3 and 4) (HLA-A2 (+) -MSC-siCON) or siRNA for HLA-A2 (SEQ ID NO: 1 and 2) (HLA-A2 (+) -MSC-siHLA-A2), and then co-incubated with Raw 264.7 cells that induced an inflammatory response. Subsequently, the amount of secreted mTNF-α was examined in each Raw 264.7 cell.
[0075] Specifically, mesenchymal stem cells of batches G027, G074, G171, G610, G028, or G257 were treated with control siRNA (HLA-A2(+)-MSC-siCON) or siRNA targeting HLA-A2 (HLA-A2(+)-MSC-siHLA-A2) to prepare cells. Then, 2×10 MSCs were plated in each well using RPMI medium containing LPS at a concentration of 1 μg / ml. 4 Raw24.7 cells and 2×10 4 After 24 hours, the culture medium was collected and the amount of secreted mTNF-α was analyzed using a mouse TNF-α immunoassay kit (R&D Systems).
[0076] As a result, when the mesenchymal stem cells expressing HLA-A2 were treated with the control siRNA (HLA-A2(+)-MSC-siCON), the secretion of TNF-α decreased. On the other hand, when the mesenchymal stem cells expressing HLA-A2 were treated with the siRNA targeting HLA-A2 (HLA-A2(+)-MSC-siHLA-A2), the secretion of TNF-α did not decrease significantly ( Figure 3 ).
[0077] In addition, the reduction rate of TNF-α secretion in the case of treating HLA-A2-expressing mesenchymal stem cells with control siRNA (HLA-A2(+)-MSC-siCON) and in the case of treating HLA-A2-expressing mesenchymal stem cells with siRNA targeting HLA-A2 (HLA-A2(+)-MSC-siHLA-A2) was compared. As a result, in the case of HLA-A2-expressing mesenchymal stem cells treated with siRNA targeting HLA-A2, the reduction rate of TNF-α secretion decreased, indicating that the inhibition of HLA-A2 expression in mesenchymal stem cells leads to a decrease in the inflammatory inhibitory effect of mesenchymal stem cells ( Figure 4 ).
[0078] Example 4: Identification of changes in HLA-A2 expression levels in mesenchymal stem cells based on their passage number
[0079] To identify whether the expression of HLA-A2 in cord blood-derived mesenchymal stem cells varies according to their passage number, mesenchymal stem cells were first isolated from cord blood, and then the expression pattern of HLA-A2 was analyzed using mesenchymal stem cells that had been passaged twice (passage 2, P2, G028) and mesenchymal stem cells that had been passaged six times (passage 6, P6, G171).
[0080] FACS analysis was performed using an anti-HLA-A2 antibody in the same manner as in Example 1. The results showed that all mesenchymal stem cells that had been passaged 2 and 6 expressed HLA-A2 at a level of 90% or more, indicating that mesenchymal stem cells expressed HLA-A2 ( Figure 5 ).
[0081] Example 5: Identification of the therapeutic effect of cord blood-derived mesenchymal stem cells expressing HLA-A2 on the cell surface using a bronchopulmonary dysplasia mouse model
[0082] Bronchopulmonary dysplasia is a disease characterized by abnormal lung structure and stunted lung development. It is an inflammatory disease that causes lung damage due to excessive lung inflammation induced during high-concentration oxygen therapy administered to newborns with respiratory distress using ventilators. To date, there is no basic treatment and management method for Bronchopulmonary dysplasia worldwide.
[0083] Therefore, it was determined whether therapeutic effects such as regeneration of immature lung tissue and suppression of inflammation were observed when umbilical cord blood-derived mesenchymal stem cells expressing HLA-A2 on the cell surface were administered to a bronchopulmonary dysplasia mouse model.
[0084] Specifically, in order to reflect the condition of high oxygen concentration caused by treatment with an oxygen ventilator after birth, pregnant female mice were obtained and given birth. Then, the newborn mice within 10 hours after birth were moved to cages with normal or high oxygen concentrations and raised. Each mother mouse that gave birth was also moved to the same cage to raise newborn mice and raised them. Here, considering that the number of newborn mice delivered from pregnant mothers may fluctuate, and that the average mortality rate of newborn mice raised under high oxygen concentration conditions is about 50%, a total of 18 mice were raised in each group, so the final mice in each group were 9. Of these 9 mice, 3 mice were used for morphological analysis of lung tissue, 3 mice were used for alveolar solution extraction to identify inflammatory substances, and the remaining 3 mice were used for RNA or protein analysis. The description of each group is shown in Table 2 below.
[0085] [Table 2]
[0086]
[0087]
[0088] On the third day after birth, newborn mice were intraperitoneally injected with 50 mg / ml of Zoletil 50 and 23.32 mg / ml of Rompun as anesthetics. Then, PBS, mesenchymal stem cells expressing HLA-A2 (HLA-A2(+)), or mesenchymal stem cells treated with control siRNA (siCON) or siRNA targeting HLA-A2 (siHLA-A2) were injected into the airways of newborn mice. Here, for the mesenchymal stem cell administration group, 5×10 5 Mesenchymal stem cells were suspended in 50 μl of PBS and administered to each newborn mouse once. Then, on the 14th day of birth, the anesthetic was injected intraperitoneally into the mice again. Lung tissue was collected and analyzed. Lung tissue blocks that had been fixed in 4% formaldehyde for 24 hours were embedded in paraffin, cut into 4 μm thick sections, histologically stained with hematoxylin / eosin, and then histologically observed with an optical microscope. In this way, the therapeutic effect of mesenchymal stem cells expressing HLA-A2 on the lung tissue that had been induced to damage by high oxygen concentration was evaluated by comparison.
[0089] As a result, the group to which only PBS was administered after the injury was caused by high oxygen concentration (hyperoxia-PBS) had severe alveolar damage compared to the lung tissue of the group under normal oxygen concentration. For this alveolar damage, the protective or therapeutic effect of the group or administration group (hyperoxia-HLA-A2(+)-MSC-siCON) expressing HLA-A2 of the present invention on the alveoli was similar to that of the group under normal oxygen concentration. On the other hand, almost no therapeutic effect was observed in the administration group (hyperoxia-HLA-A2(+)-MSC-siHLA-A2). From these results, it can be determined that umbilical cord blood-derived mesenchymal stem cells expressing HLA-A2 can treat lung inflammation and lung injury caused by high oxygen concentration ( Figure 6 ).
[0090] In addition, the extent of alveolar damage was quantified as the mean linear index. Figure 7 As shown, the bronchopulmonary dysplasia model group (hyperoxia-PBS) had a significantly higher mean linear index compared to the normal group due to impaired alveolar development. It can be seen that the group administered with mesenchymal stem cells expressing HLA-A2 or the drug administration group (hyperoxia-HLA-A2(+)-MSC-siCON) had a significantly reduced mean linear index due to improved lung damage. On the other hand, the drug administration group (hyperoxia-HLA-A2(+)-MSC-siHLA-A2) did not have a significantly reduced mean linear index due to poor treatment effect ( Figure 7 ).
[0091] Example 6: Identification of the therapeutic effect of cord blood-derived mesenchymal stem cells expressing HLA-A2 on the cell surface using an Alzheimer's disease mouse model
[0092] As an Alzheimer's disease mouse model, 6-month-old 5XFAD mice (Jackson Laboratory, USA) were used. In 5XFAD mice, beta-amyloid protein is produced in brain tissue from 2 months of age; beta-amyloid protein accumulates in brain tissue at 4 months of age; and cognitive impairment appears at about 6 months of age. 5 μl of anesthetic / mouse body weight (g) was intraperitoneally administered to 6-month-old 5XFAD mice, wherein the anesthetic was a mixture of Zoletil, Rompun, and saline in a ratio of 4:1:5.
[0093] In order to perform intraventricular administration of the mesenchymal stem cells expressing HLA-A2 isolated in Example 1, the guide cannula was inserted into the target position (from the anterior fontanelle, front / back: -0.22mm, medial / lateral: 1.0mm, back / side: 2.5mm), and then fixed with screws placed around the cannula. Then, the mice were given a recovery period of 6 to 8 days for recovery. Then, the mesenchymal stem cells expressing HLA-A2 derived from umbilical cord blood were transferred to a Hamilton syringe, and its internal cannula was then placed in the guide cannula. Intraventricular injection was performed at an infusion rate of 0.5μl / min. Here, the description of each group is shown in Table 3 below.
[0094] [Table 3]
[0095]
[0096] At the time of sacrifice, an appropriate amount of anesthetic was administered intraperitoneally according to body weight, and then cardiac perfusion was performed using a peristaltic pump. First, to expose the heart, the skin, diaphragm, and ribs of the mouse were cut, and the pump tube was connected to the left ventricle. Then, PBS was circulated in the body to drain the blood.
[0097] After that, brain tissue was collected and frozen at -80 ° C. Brain tissue was lysed using lysis buffer and an ultrasonic instrument. Then, according to the Bradford assay, brain tissue lysate was diluted and used. A cytokine ELISA KIT suitable for measuring lysate (e.g., brain tissue lysate) was used. Proinflammatory cytokines were analyzed using TNF-α ELISA kits (PeproTech, 900K54EK) and IFN-γ ELISA kits (RayBio, ELM-IFNg-CL). Anti-inflammatory cytokines were analyzed using CD163 ELISA kits (LSBio, Catalog No. LS-F9079) and Arg-1 ELISA kits (LSBio, Catalog No. LS-F6864).
[0098] As a result, under both conditions of test A (week 12) and test B (week 20) of the experimental group in which the mesenchymal stem cells expressing HLA-A2 were administered once and the experimental group in which the mesenchymal stem cells expressing HLA-A2 were administered repeatedly, TNF-α and INF-γ were reduced compared with the control group. In particular, in the experimental group in which the mesenchymal stem cells expressing HLA-A2 were administered repeatedly, TNF-α was reduced in a statistically significant manner; and in the experimental group in which the mesenchymal stem cells expressing HLA-A2 were administered once, INF-γ was reduced in a statistically significant manner ( Figure 8 and 9 ). Based on these results, it was confirmed that the anti-inflammatory effect can be maintained even after a period of time when mesenchymal stem cells are repeatedly administered.
[0099] In addition, CD163 and arginase-1 (Arg-1), which are generally considered to be anti-inflammatory cytokines in brain tissue, were analyzed by ELISA. As a result, under the conditions of test A (week 12) and test B (week 20) of the experimental group of mesenchymal stem cells expressing HLA-A2 and the experimental group of mesenchymal stem cells expressing HLA-A2 with a single administration, CD163 and Arg-1 increased compared with the control group. In particular, compared with the control group, in the experimental group of mesenchymal stem cells expressing HLA-A2 with repeated administration, CD163 increased in a statistically significant manner; and in the experimental group of mesenchymal stem cells expressing HLA-A2 with a single administration and the experimental group of mesenchymal stem cells expressing HLA-A2 with repeated administration, Arg-1 increased in a statistically significant manner ( Fig.10 and 11 ). Based on these results, it was confirmed that the anti-inflammatory effect can be maintained even after a period of time when mesenchymal stem cells are repeatedly administered. Sequence Listing <110> MEDIPOST CO., LTD. <120> Pharmaceutical composition containing mesenchymal stem cells as an effective ingredient for preventing or treating inflammatory diseases <130> PCB903022MOG <150> US 62 / 680,748 <151> 2018-06-05 <160> 4 <170> SIPOSequenceListing 1.0 <210> 1 <211> twenty one <212> DNA <213> Artificial Sequence <400> 1 guucguguag gcauaaugut t 21 <210> 2 <211> twenty one <212> DNA <213> Artificial Sequence <400> 2 acauuaugcc uacacgaact t 21 <210> 3 <211> twenty one <212> DNA <213> Artificial Sequence <400> 3 ccuacgccac caauuucgut t 21 <210> 4 <211> twenty one <212> DNA <213> Artificial Sequence <400> 4 acgaaauugg uggcguaggt t 21
Claims
1. A use of a pharmaceutical composition, characterized in that: For preparing a drug for treating inflammatory diseases, the pharmaceutical composition comprises: Mesenchymal stem cells expressing HLA-A2 at a level of 70% or more on their surface, wherein the mesenchymal stem cells are derived from umbilical cord blood, wherein the inflammatory disease is Alzheimer's disease or bronchopulmonary dysplasia (BPD).
2. The use according to claim 1, characterized in that The mesenchymal stem cells express any one selected from the following group: CD73, CD90, CD105, CD166, and combinations thereof on their surface; and do not express any one selected from the following group: CD14, CD34, CD45, HLA-DR, and combinations thereof.
3. The use according to claim 1, characterized in that The mesenchymal stem cells express any one of CD73, CD90, CD105 and CD166 at a level of 70% or more on their surface, and express any one of CD14, CD34, CD45 and HLA-DR at a level of 1% or less.
4. The use according to claim 1, characterized in that The mesenchymal stem cells express HLA-A2 at a level of 75% or more, express any one of CD73, CD90, CD105 and CD166 at a level of 70% or more, and express any one of CD14, CD34, CD45 and HLA-DR at a level of 1% or less on their surface.
